@JTOonline

@JTOonline

Most recents (5)

Stephen V Liu

@StephenVLiu

#OncoAlert Online now @JTOonline is the ORIENT-11 trial of sintilimab + platinum/pemetrexed in NSCLC. Simultaneous publication with #VPS20 #WCLC20 @IASLC presentation. Randomized phase III study of chemotherapy +/- anti PD-1 antibody sintilimab. #LCSM

jto.org/article/S1556-…

Sintilimab is a PD1 antibody and the phase Ib of sintilimab with platinum/pem had RR 68.4% and mPFS 11.4m. Phase III included 397 patients in 47 hospitals in China with treatment naive advanced EGFR/ALK wild type non-squamous NSCLC, stratified by PDL1 expression (22C3).

Enrolled in < 1y! All patients received 4 cycles of carboplatin AUC 5 with pemetrexed 500mg/m2 q21d and randomized 2:1 to sintilimab 200mg flat dose or placebo followed by sintilimab/placebo maintenance. After median f/u of 8.9m, primary endpoint met: PFS 8.9m vs 5m (HR 0.482).

Read 7 tweets

Stephen V Liu

@StephenVLiu

@IASLC

#VPS20 Paul Baas presents the highly anticipated Checkmate-743 trial: a randomized phase III study of nivolumab + ipilimumab vs platinum + pemetrexed chemotherapy as 1L treatment in unresectable malignant pleural mesothelioma. Mature dataset. #MPM #LCSM #WCLC20 @IASLC

@IASLC

#VPS20 Positive #MPM trial! Nivolumab and ipilimumab provided OS benefit over chemo with OS HR 0.74. mOS 18.1m with nivo/ipi and 14.1 with pt/pem. 2y OS 41% vs 27%. RR comparable, more durable in the IO arm. Substantial benefit in the non-epithelioid subset! #WCLC20 @IASLC

@IASLC

#VPS20 Nivolumab + ipilimumab with better outcomes in the PDL1 positive subset. Toxicity with no new signals but 23% of patients in the nivo/ipi arm discontinued part of therapy for toxicity. A new standard emerges for #MPM with this trial. #WCLC20 @IASLC

Read 4 tweets

Stephen V Liu

@StephenVLiu

@HornLeora

#VPS20 Eagerly awaited results of the eXalt3 trial of ensartinib vs crizotinib in #ALK #NSCLC presented by @HornLeora - straightforward randomized design. #LCSM #WCLC20 @IASLC

@IASLC

#VPS20 Demographics as expected. BIRC mPFS 25.8m vs 12.7m with HR 0.51 and impressive waterfall plot and durable responses. #LCSM #WCLC20 @IASLC

@IASLC

#VPS20 OS is immature. No unexpected safety signals. Overall, ensartinib performed well and likely will represent another option in #ALK NSCLC but where to insert this 2nd gen TKI in our treatment algorithm remains to be seen. #LCSM #WCLC20 @IASLC

Read 3 tweets

Stephen V Liu

@StephenVLiu

@IASLC

#VPS20 The ORIENT-11 trial presented by Dr. Zhang: 1L platinum/pemetrexed +/- sintilimab (anti-PD1) in non-sq NSCLC. Good design: 2:1 randomization, no EGFR/ALK, stratified by PDL1, crossover included. #LCSM @IASLC #WCLC20

@IASLC

#VPS20 Positive study with PFS HR 0.482 favoring sintilimab, mPFS 8.9m vs 5.0m which is very comparable to KEYNOTE-189. Hits all the right subgroups and stepwise benefit by PDL1 expression. Important to have these data in an East Asian population. #LCMS @IASLC #WCLC20

@IASLC

#VPS20 OS is immature but RR favors sintilimab (51.9% vs 29.8%), time to response 1.5 months and median duration not reached. No unexpected safety signals noted with this novel PD1 inhibitor in an East Asian population. #LCSM @IASLC #WCLC20

Read 4 tweets

Stephen V Liu

@StephenVLiu

@marinagarassino

#VPS20 Presidential symposium overview of #COVID19 and thoracic cancers by @marinagarassino. First case in Italy reported 2/20/20 and we've learned a great deal since then about COVID outcomes in patients with cancer. #LCSM @IASLC #WCLC20

@IASLC

#VPS20 The UKCCMP registry noted a high mortality rate in patients with cancer (28%) and 22% of patients had disruption in cancer care. Mortality in the CCC19 registry was reported at 16% but higher (26%) in patients with lung cancer. #LCSM @IASLC #WCLC20

@marinagarassino

#VPS20 #TERAVOLT is an impressive, global registry led by @marinagarassino @HornLeora including only patients with thoracic cancers and #COVID19. Mortality reported at 35.5% and outcomes vary with PS. TERAVOLT now has over 1000 cases! #LCSM @IASLC #WCLC20

Read 3 tweets

Discover and read the best of Twitter Threads about #vps20

Most recents (5)

Related hashtags

Discover and read the best of Twitter Threads about #vps20

Most recents (5)

Related hashtags

Did Thread Reader help you today?